PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för AZD3965. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

29 hits

Bibliografisk träff 2025-05-22

Mitochondrial fission factor drives an actionable metabolic vulnerability in multiple myeloma.

Cantafio MEG, Valentino I, Torcasio R, Ganino L, Veneziano C, Murfone P, Mesuraca M, Perrotta I, Tallarigo F, Agosti V, De Marco C, Pasqua T, Giallongo C, Cappello AR, Fiorillo M, Gentile M, Tibullo D, Viglietto G, Neri A, Amodio N.

Haematologica · research support, non-u.s. gov't; research-article; journal article · DOI 10.3324/haematol.2025.287526

Bibliografisk träff 2025-05-09

Gastric cancer cells shuttle lactate to induce inflammatory CAF-like phenotype and function in bone marrow-derived mesenchymal stem cells.

Huang F, Cao X, Mei J, Wu C, Zhu W, Sun L, Dai C, Wang M.

Mol Immunol · journal article · DOI 10.1016/j.molimm.2025.05.002

Bibliografisk träff 2025-02-26

Lactate dehydrogenase B deficiency-dependent hyperlactatemia coordinates with necroptosis to worsen septic liver and kidney injuries.

Jia Y, Qiu C, Zhu G, Jin SW, Lai JM, Shen Y, Zhu HP, Yang XH, Ye XM, Mo SJ.

Biochem Biophys Res Commun · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bbrc.2025.151552

Bibliografisk träff 2025-01-14

2-[18F]Fluoropropionic Acid PET Imaging of Doxorubicin-Induced Cardiotoxicity.

Azcona JA, Wacker AS, Lee CH, Fung EK, Jeitner TM, Manzo OL, Di Lorenzo A, Babich JW, Amor-Coarasa A, Kelly JM.

Mol Imaging Biol · research-article; journal article · DOI 10.1007/s11307-024-01978-y

Bibliografisk träff 2025-01-14

Lactate accumulation promotes immunosuppression and fibrotic transformation of bone marrow microenvironment in myelofibrosis.

Spampinato M, Giallongo C, Giallongo S, Spina E, Duminuco A, Longhitano L, Caltabiano R, Salvatorelli L, Broggi G, Pricoco EP, Del Fabro V, Dulcamare I, DI Mauro AM, Romano A, Di Raimondo F, Li Volti G, Palumbo GA, Tibullo D.

J Transl Med · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/s12967-025-06083-4

Bibliografisk träff 2024-10-28

Emodin regulated lactate metabolism by inhibiting MCT1 to delay non-small cell lung cancer progression.

Zhang F, Gu T, Li J, Zhu Y, Chu M, Zhou Q, Liu J.

Hum Cell · journal article · DOI 10.1007/s13577-024-01140-4

Bibliografisk träff 2023-11-28

Effects of Lactate Transport Inhibition by AZD3965 in Muscle-Invasive Urothelial Bladder Cancer.

Silva A, Félix A, Cerqueira M, Gonçalves CS, Sampaio-Marques B, Longatto-Filho A, Baltazar F, Afonso J.

Pharmaceutics · research-article; journal article · DOI 10.3390/pharmaceutics15122688

Bibliografisk träff 2023-04-01

A Phase I Dose-escalation Study of AZD3965, an Oral Monocarboxylate Transporter 1 Inhibitor, in Patients with Advanced Cancer.

Halford S, Veal GJ, Wedge SR, Payne GS, Bacon CM, Sloan P, Dragoni I, Heinzmann K, Potter S, Salisbury BM, Chénard-Poirier M, Greystoke A, Howell EC, Innes WA, Morris K, Plummer C, Rata M, Petrides G, Keun HC, Banerji U, Plummer R.

Clin Cancer Res · research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; journal article · DOI 10.1158/1078-0432.ccr-22-2263

Bibliografisk träff 2023-03-08

Targeting cancer lactate metabolism with synergistic combinations of synthetic catalysts and monocarboxylate transporter inhibitors.

Bridgewater HE, Bolitho EM, Romero-Canelón I, Sadler PJ, Coverdale JPC.

J Biol Inorg Chem · research support, non-u.s. gov't; research-article; journal article · DOI 10.1007/s00775-023-01994-3

Bibliografisk träff 2022-11-07

Antitumor effects of lactate transport inhibition on esophageal adenocarcinoma cells.

Grasa L, Chueca E, Arechavaleta S, García-González MA, Sáenz MÁ, Valero A, Hördnler C, Lanas Á, Piazuelo E.

J Physiol Biochem · research-article; journal article · DOI 10.1007/s13105-022-00931-3

Bibliografisk träff 2022-05-26

Simultaneous targeting of glycolysis and oxidative phosphorylation as a therapeutic strategy to treat diffuse large B-cell lymphoma.

Noble RA, Thomas H, Zhao Y, Herendi L, Howarth R, Dragoni I, Keun HC, Vellano CP, Marszalek JR, Wedge SR.

Br J Cancer · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/s41416-022-01848-w

Bibliografisk träff 2021-12-29

In Vivo Anticancer Activity of AZD3965: A Systematic Review.

Silva A, Antunes B, Batista A, Pinto-Ribeiro F, Baltazar F, Afonso J.

Molecules · meta-analysis; systematic review; review-article; journal article · DOI 10.3390/molecules27010181

Bibliografisk träff 2021-05-07

γ-Hydroxybutyric Acid-Ethanol Drug-Drug Interaction: Reversal of Toxicity with Monocarboxylate Transporter 1 Inhibitors.

Rodriguez-Cruz V, Morris ME.

J Pharmacol Exp Ther · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1124/jpet.121.000566

Bibliografisk träff 2021-02-02

In Vitro and In Vivo Characterization of MCT1 Inhibitor AZD3965 Confirms Preclinical Safety Compatible with Breast Cancer Treatment.

Benyahia Z, Blackman MCNM, Hamelin L, Zampieri LX, Capeloa T, Bedin ML, Vazeille T, Schakman O, Sonveaux P.

Cancers (Basel) · research-article; journal article · DOI 10.3390/cancers13030569

Bibliografisk träff 2020-09-13

Effects of a monocarboxylate transport 1 inhibitor, AZD3965, on retinal and visual function in the rat.

Allen AE, Martin EA, Greenwood K, Grant C, Vince P, Lucas RJ, Redfern WS.

Br J Pharmacol · research-article; journal article · DOI 10.1111/bph.15239

Bibliografisk träff 2020-06-26

Tracing Nutrient Flux Following Monocarboxylate Transporter-1 Inhibition with AZD3965.

Braga M, Kaliszczak M, Carroll L, Schug ZT, Heinzmann K, Baxan N, Benito A, Valbuena GN, Stribbling S, Beckley A, Mackay G, Mauri F, Latigo J, Barnes C, Keun H, Gottlieb E, Aboagye EO.

Cancers (Basel) · research-article; journal article · DOI 10.3390/cancers12061703

Bibliografisk träff 2020-06-11

In Vitro and In Vivo Efficacy of AZD3965 and Alpha-Cyano-4-Hydroxycinnamic Acid in the Murine 4T1 Breast Tumor Model.

Guan X, Morris ME.

AAPS J · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1208/s12248-020-00466-9

Bibliografisk träff 2020-04-01

Correction: A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965.

McNeillis R, Greystoke A, Walton J, Bacon C, Keun H, Siskos A, Petrides G, Leech N, Jenkinson F, Bowron A, Halford S, Plummer R.

Br J Cancer · published erratum; correction · DOI 10.1038/s41416-020-0801-2

Bibliografisk träff 2020-02-20

A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965.

McNeillis R, Greystoke A, Walton J, Bacon C, Keun H, Siskos A, Petrides G, Leech N, Jenkinson F, Bowron A, Halford S, Plummer R.

Br J Cancer · research support, non-u.s. gov't; research-article; journal article; case reports · DOI 10.1038/s41416-020-0727-8

Bibliografisk träff 2020-01-15

Monocarboxylate transporter 1 blockade with AZD3965 inhibits lipid biosynthesis and increases tumour immune cell infiltration.

Beloueche-Babari M, Casals Galobart T, Delgado-Goni T, Wantuch S, Parkes HG, Tandy D, Harker JA, Leach MO.

Br J Cancer · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/s41416-019-0717-x

Bibliografisk träff 2019-12-10

Pharmacokinetics of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Mice: Potential Enterohepatic Circulation and Target-Mediated Disposition.

Guan X, Morris ME.

Pharm Res · research-article; journal article · DOI 10.1007/s11095-019-2735-z

Bibliografisk träff 2019-04-22

Treatment of γ-Hydroxybutyric Acid and γ-Butyrolactone Overdose with Two Potent Monocarboxylate Transporter 1 Inhibitors, AZD3965 and AR-C155858.

Follman KE, Morris ME.

J Pharmacol Exp Ther · research-article; journal article; research support, n.i.h., extramural · DOI 10.1124/jpet.119.256503

Bibliografisk träff 2019-01-07

Cellular Uptake of MCT1 Inhibitors AR-C155858 and AZD3965 and Their Effects on MCT-Mediated Transport of L-Lactate in Murine 4T1 Breast Tumor Cancer Cells.

Guan X, Rodriguez-Cruz V, Morris ME.

AAPS J · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1208/s12248-018-0279-5

Bibliografisk träff 2018-03-31

Development and validation of a liquid chromatography tandem mass spectrometry assay for AZD3965 in mouse plasma and tumor tissue: Application to pharmacokinetic and breast tumor xenograft studies.

Guan X, Ruszaj D, Morris ME.

J Pharm Biomed Anal · research-article; journal article · DOI 10.1016/j.jpba.2018.03.061

Bibliografisk träff 2017-09-18

MCT1 Inhibitor AZD3965 Increases Mitochondrial Metabolism, Facilitating Combination Therapy and Noninvasive Magnetic Resonance Spectroscopy.

Beloueche-Babari M, Wantuch S, Casals Galobart T, Koniordou M, Parkes HG, Arunan V, Chung YL, Eykyn TR, Smith PD, Leach MO.

Cancer Res · research support, non-u.s. gov't; research-article; journal article · DOI 10.1158/0008-5472.can-16-2686

Bibliografisk träff 2017-05-25

Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt's lymphoma anti-tumor activity.

Curtis NJ, Mooney L, Hopcroft L, Michopoulos F, Whalley N, Zhong H, Murray C, Logie A, Revill M, Byth KF, Benjamin AD, Firth MA, Green S, Smith PD, Critchlow SE.

Oncotarget · research-article; journal article · DOI 10.18632/oncotarget.18215

Bibliografisk träff 2017-04-06

Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma.

Noble RA, Bell N, Blair H, Sikka A, Thomas H, Phillips N, Nakjang S, Miwa S, Crossland R, Rand V, Televantou D, Long A, Keun HC, Bacon CM, Bomken S, Critchlow SE, Wedge SR.

Haematologica · research-article; journal article · DOI 10.3324/haematol.2016.163030

Bibliografisk träff 2014-10-03

Inhibition of monocarboxylate transporter-1 (MCT1) by AZD3965 enhances radiosensitivity by reducing lactate transport.

Bola BM, Chadwick AL, Michopoulos F, Blount KG, Telfer BA, Williams KJ, Smith PD, Critchlow SE, Stratford IJ.

Mol Cancer Ther · research support, non-u.s. gov't; research-article; journal article · DOI 10.1158/1535-7163.mct-13-1091

Bibliografisk träff 2013-11-25

Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer.

Polański R, Hodgkinson CL, Fusi A, Nonaka D, Priest L, Kelly P, Trapani F, Bishop PW, White A, Critchlow SE, Smith PD, Blackhall F, Dive C, Morrow CJ.

Clin Cancer Res · research support, non-u.s. gov't; research-article; journal article · DOI 10.1158/1078-0432.ccr-13-2270

Go to research.

Publications in the selection

Mitochondrial fission factor drives an actionable metabolic vulnerability in multiple myeloma.

Gastric cancer cells shuttle lactate to induce inflammatory CAF-like phenotype and function in bone marrow-derived mesenchymal stem cells.

Lactate dehydrogenase B deficiency-dependent hyperlactatemia coordinates with necroptosis to worsen septic liver and kidney injuries.

2-[<sup>18</sup>F]Fluoropropionic Acid PET Imaging of Doxorubicin-Induced Cardiotoxicity.

Lactate accumulation promotes immunosuppression and fibrotic transformation of bone marrow microenvironment in myelofibrosis.

Emodin regulated lactate metabolism by inhibiting MCT1 to delay non-small cell lung cancer progression.

Effects of Lactate Transport Inhibition by AZD3965 in Muscle-Invasive Urothelial Bladder Cancer.

A Phase I Dose-escalation Study of AZD3965, an Oral Monocarboxylate Transporter 1 Inhibitor, in Patients with Advanced Cancer.

Targeting cancer lactate metabolism with synergistic combinations of synthetic catalysts and monocarboxylate transporter inhibitors.

Antitumor effects of lactate transport inhibition on esophageal adenocarcinoma cells.

Simultaneous targeting of glycolysis and oxidative phosphorylation as a therapeutic strategy to treat diffuse large B-cell lymphoma.

In Vivo Anticancer Activity of AZD3965: A Systematic Review.

<i>γ</i>-Hydroxybutyric Acid-Ethanol Drug-Drug Interaction: Reversal of Toxicity with Monocarboxylate Transporter 1 Inhibitors.

In Vitro and In Vivo Characterization of MCT1 Inhibitor AZD3965 Confirms Preclinical Safety Compatible with Breast Cancer Treatment.

Effects of a monocarboxylate transport 1 inhibitor, AZD3965, on retinal and visual function in the rat.

Tracing Nutrient Flux Following Monocarboxylate Transporter-1 Inhibition with AZD3965.

In Vitro and In Vivo Efficacy of AZD3965 and Alpha-Cyano-4-Hydroxycinnamic Acid in the Murine 4T1 Breast Tumor Model.

Correction: A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965.

A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965.

Monocarboxylate transporter 1 blockade with AZD3965 inhibits lipid biosynthesis and increases tumour immune cell infiltration.

Pharmacokinetics of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Mice: Potential Enterohepatic Circulation and Target-Mediated Disposition.

Treatment of <i>γ</i>-Hydroxybutyric Acid and <i>γ</i>-Butyrolactone Overdose with Two Potent Monocarboxylate Transporter 1 Inhibitors, AZD3965 and AR-C155858.

Cellular Uptake of MCT1 Inhibitors AR-C155858 and AZD3965 and Their Effects on MCT-Mediated Transport of L-Lactate in Murine 4T1 Breast Tumor Cancer Cells.

Development and validation of a liquid chromatography tandem mass spectrometry assay for AZD3965 in mouse plasma and tumor tissue: Application to pharmacokinetic and breast tumor xenograft studies.

MCT1 Inhibitor AZD3965 Increases Mitochondrial Metabolism, Facilitating Combination Therapy and Noninvasive Magnetic Resonance Spectroscopy.

Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt's lymphoma anti-tumor activity.

Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma.

Inhibition of monocarboxylate transporter-1 (MCT1) by AZD3965 enhances radiosensitivity by reducing lactate transport.

Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer.